CN105816488A - Drug capable of resisting dementia and myocardial ischemia, and biologically-active substances, preparation method and application thereof - Google Patents
Drug capable of resisting dementia and myocardial ischemia, and biologically-active substances, preparation method and application thereof Download PDFInfo
- Publication number
- CN105816488A CN105816488A CN201610007286.5A CN201610007286A CN105816488A CN 105816488 A CN105816488 A CN 105816488A CN 201610007286 A CN201610007286 A CN 201610007286A CN 105816488 A CN105816488 A CN 105816488A
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- hibiscus
- group
- hibiscus esculentus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 229940079593 drug Drugs 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 206010012289 Dementia Diseases 0.000 title claims abstract description 25
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 25
- 239000013543 active substance Substances 0.000 title abstract description 4
- 239000000284 extract Substances 0.000 claims abstract description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000011347 resin Substances 0.000 claims abstract description 21
- 229920005989 resin Polymers 0.000 claims abstract description 21
- 238000001179 sorption measurement Methods 0.000 claims abstract description 16
- 229930013930 alkaloid Natural products 0.000 claims abstract description 13
- 150000003431 steroids Chemical class 0.000 claims abstract description 13
- 150000002989 phenols Chemical class 0.000 claims abstract description 10
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 6
- 240000005959 Abelmoschus manihot Species 0.000 claims description 76
- 235000001642 Hibiscus manihot Nutrition 0.000 claims description 75
- 239000000243 solution Substances 0.000 claims description 47
- 239000000287 crude extract Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 30
- 240000004507 Abelmoschus esculentus Species 0.000 claims description 27
- 235000003934 Abelmoschus esculentus Nutrition 0.000 claims description 27
- 238000010828 elution Methods 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 20
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 238000013461 design Methods 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 239000003480 eluent Substances 0.000 claims description 16
- 238000004064 recycling Methods 0.000 claims description 16
- -1 alkaloid compound Chemical class 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 15
- 239000012488 sample solution Substances 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 241000416196 Laccophilus congener Species 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 238000005282 brightening Methods 0.000 claims description 3
- 239000004067 bulking agent Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 235000013599 spices Nutrition 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 238000012360 testing method Methods 0.000 abstract description 10
- 239000000039 congener Substances 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 19
- 239000000469 ethanolic extract Substances 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 239000013558 reference substance Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 9
- 239000012362 glacial acetic acid Substances 0.000 description 9
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 9
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 9
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 9
- 235000005493 rutin Nutrition 0.000 description 9
- 229960004555 rutoside Drugs 0.000 description 9
- 102100033639 Acetylcholinesterase Human genes 0.000 description 7
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 6
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 6
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 6
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 6
- 229940074393 chlorogenic acid Drugs 0.000 description 6
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 6
- 235000001368 chlorogenic acid Nutrition 0.000 description 6
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 6
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 6
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 6
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000009189 diving Effects 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 4
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 4
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 3
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000008899 fufang danshen Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 229930014456 matrine Natural products 0.000 description 3
- 230000005056 memory consolidation Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 3
- 235000012141 vanillin Nutrition 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 241001075517 Abelmoschus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- 101000777312 Rattus norvegicus Choline kinase alpha Proteins 0.000 description 2
- 101000777311 Rattus norvegicus Choline/ethanolamine kinase Proteins 0.000 description 2
- 101001047152 Rattus norvegicus UMP-CMP kinase Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 241000707822 Ulmus glabra Species 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960004526 piracetam Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000001075 Abelmoschus manihot Nutrition 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a drug capable of resisting dementia and myocardial ischemia, and biologically-active substances, a preparation method and application thereof. Specifically, the invention relates to a Hibiseu Smanihot extract, and a preparation method and application thereof. Biologically-active substances like phenols, alkaloids and steroids in Hibiseu Smanihot are obtained by subjecting Hibiseu Smanihot or congener thereof and chemically related plants thereof to extraction with water or ethanol and then carrying out separation and enrichment by using chromatography like macroporous adsorption resin. According to testing results of a dementia model and myocardial ischemia model, the Hibiseu Smanihot extract prepared in the invention has effect in resisting dementia and myocardial ischemia and can be applied to drugs, health-care products, foodstuffs, etc.
Description
Technical field
The invention belongs to medicine and research and develop field with bioactive substance, relate to a kind of medicine and bioactive substance, particularly to a kind of, there is dementia and the prepared product of function of resisting myocardial ischemia, preparation method and application.
Background technology
Dementia is the disturbance of intelligence of a kind of persistence, and the cause of disease is sufficiently complex, and existing inherited genetic factors has again posteriori environmental effect and induction, and the disease of dementia can be caused to be up to hundred She's kinds.Senile dementia still can only be played the effect improving symptom by the medicine of listing at present.Therefore, up to the present, effective treatment means of control disease process is still lacked.
Myocardial infarction is one of the commonly encountered diseases of cardiovascular disease, frequently-occurring disease, and during acute attack, mortality rate is higher, causes in medical circle and payes attention to widely.Myocardial ischemia (myocardialischemia) is that the hemoperfusion of heart reduces, the oxygen supply causing heart reduces, and energy metabolism of myocardial is abnormal, it is impossible to support a kind of pathological state of normal heart action, presenting multiple trend at present, market medicine is numerous and diverse and has certain side effect.Chinese medicine relies on its multicomponent, the advantage of Mutiple Targets, has more development prospect.
Hibiscus manihot L. is Malvaceae Abelmoschus plant, and containing various bioactivators, wherein the content of total flavones is up to 6%, is in the first place of currently known plant.It has been investigated that Hibiscus manihot L. and congener have bioactive chemical composition containing phenols, alkaloids, steroid etc..Active component in Hibiscus manihot L. is used solvent extraction method and chromatography such as macroporous adsorbent resin to carry out separation and concentration by the present invention, and carries out prepared product combination, obtains dementia and medicaments for resisting myocardial ischemia and active substance, thus advances the innovation of medicine and health-oriented products.
Summary of the invention
It is an object of the invention to provide and a kind of there is dementia and the medicine of activity against myocardial ischemia and bioactive substance, offer its preparation method is provided, third object of the present invention is to provide its quality testing and control method, and fourth object of the present invention is to provide a kind of new application of Hibiscus manihot L..
The technical scheme is that
A kind of Hibiscus esculentus L. extract, including: phenolic compound, alkaloid compound and steroid, the content of phenolic compound is 10%-90% (mass percent), the content of alkaloid compound is 1%-70% (mass percent), and the content of steroid is 1%-60% (mass percent).
Hibiscus manihot L., has another name called: vegetable Furong, also referred to as: wild Hibisci Mutabilis, and for annual herb Malvaceae Abelmoschus plant, some areas another name is glutinous dry or wych-elm skin.
The former plant of Hibiscus manihot L. congener, such as: Abelmoschus manihot （L.） Medic etc..
Hibiscus esculentus L. extract of the present invention can be extracted by the most above-mentioned medicinal plants and alternative kind thereof and form, selection part for Hibiscus manihot L. and the former plant of Hibiscus manihot L. congener is not particularly limited, can be using entirety as crude drug, the part in plant can also be chosen as crude drug, such as flower, root, stem, leaf etc., including its medicinal part and dis-medicinal part, preferably flower of Hibiscus manihot L.
Hibiscus esculentus L. extract of the present invention also can be made up of the processed goods of above-mentioned medicinal plants and alternative kind thereof, such as, make including that its medicinal part and dis-medicinal part, medical material and decoction pieces thereof extract further as crude drug.
For Hibiscus esculentus L. extract, preparation can be extracted by natural resources, can be obtained by chemosynthesis or structural modification and the approach such as biosynthesis or bioconversion.
Hibiscus esculentus L. extract of the present invention may be used for dementia and resists myocardial ischemia.
A kind of preparation containing Hibiscus esculentus L. extract, including above-mentioned Hibiscus esculentus L. extract and adjuvant.
Further, one or more during described adjuvant is preservative, antioxidant, coloring agent, thickening agent and stabilizer, bulking agent, sweeting agent, acidity agent, brightening agent or spice.
Further, the dosage form of described preparation is pharmaceutics acceptable any conventional dosage form or long-acting and slow releasing preparation, controlled release preparation, targeting preparation.Preferably, the dosage form of said preparation includes tablet, capsule, granule, oral liquid, syrup, drop pill, injection, freeze dried powder, slow releasing tablet or micropill.
The present invention also provides for the preparation method of a kind of Hibiscus esculentus L. extract, comprises the following steps:
1) using Hibiscus manihot L. or the former plant of Hibiscus manihot L. congener as crude drug；
2) utilize water or organic solvent reflux, extract, obtain crude extract；
3) by step 2) crude extract that obtains is enriched with.
In above-mentioned preparation method, described crude drug is selected from following plant and alternative kind thereof, uses position and non-usage position, medical material and decoction pieces thereof including it.
Hibiscus manihot L. (vegetable Furong, wild Hibisci Mutabilis, glutinous dry, wych-elm skin) the former plant of congener (including each position of Hibiscus manihot L.) and processed goods thereof.Preferably, described crude drug is flower of Hibiscus manihot L.
Further, the method for described enrichment is chromatography or solvent extraction.Such as: chromatography can be macroporous absorption tree, polyamide chromatography, silica gel chromatography etc..
Further, step 2) concretely comprise the following steps: by starting material with water or alcohol reflux 2-5 time, extract 0.5-3 hour every time, obtain crude extract.
That takes above-mentioned further technical scheme has the beneficial effect that the extraction ratio improving effective ingredient.
The extract of above-mentioned raw materials medicine obtains through a step enrichment or substep enrichment combination.It is specifically introduced with wherein method below.
Step 3) concretely comprise the following steps: by step 2) crude extract that obtains adds water dispersing and dissolving, obtains the aqueous solution of crude extract, making crude extract concentration in aqueous is 0.001-0.50g/mL；By the aqueous solution of crude extract by low pole or nonpolar macroporous adsorption resin, adsorption flow rate is 0.5-10BV/h, and resin column blade diameter length ratio is 1: (2-15), and sample solution concentration is 0.001-0.50g/mL, collects loading effluent, then water remove impurity 0-8BV；Utilizing volume fraction 5%-50% ethanol solution eluting 1-10BV, elution flow rate is 0.5-10BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance I；Utilizing volume fraction 50%-90% ethanol solution eluting 1-10BV, elution flow rate is 0.5-10BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance II, and enriched substance I and enriched substance II are combined to obtain Hibiscus esculentus L. extract.
Take having the beneficial effect that of above-mentioned further technical scheme to improve the content of active component in extract further, ensure the performance of activity as far as possible.
Further, in described Hibiscus esculentus L. extract, the content of phenolic compound is 10%-90% (mass percent), the content of alkaloid compound is 1%-70% (mass percent), and the content of steroid is 1%-60% (mass percent).
Hibiscus esculentus L. extract is prepared by obtained as above, add the various adjuvants that this area is conventional, or prepare any conventional dosage form as additive, preparation process routinely makes pharmaceutics acceptable any conventional dosage form, it is administered systemically preparation including capsule, tablet, granule, gel, other transmission such as long-acting and slow releasing agent, oral liquid, controlled release preparation, targeting preparation etc., can be applicable in medicine, healthy product etc..Gained preparation can use as people's medicine, veterinary drug, plant medication or use.
Known food additive such as preservative, antioxidant, coloring agent, thickening agent and stabilizer, bulking agent, sweeting agent, acidity agent, brightening agent, spice etc. can also be added and make health product or healthy product or food etc..
Hibiscus esculentus L. extract of the present invention can be prepared to have in dementia and/or medicaments for resisting myocardial ischemia again and wide sends out application.
Detailed description of the invention
Principle and feature to the present invention are described below, and example is served only for explaining the present invention, is not intended to limit the scope of the present invention.
Embodiment 1 prepares Hibiscus manihot L. compositions
1) selecting flower of Hibiscus manihot L is crude drug；
2) utilize water reflux, extract, obtain crude extract, specifically include following steps: by crude drug water reflux, extract, 2 times, extract 0.5 hour every time, obtain crude extract；
3) by step 2) crude extract that obtains is enriched with, concretely comprises the following steps:
By step 2) crude extract that obtains adds water dispersing and dissolving, obtains the aqueous solution of crude extract, and making crude extract concentration in aqueous is 0.001g/mL；By the aqueous solution of crude extract by low pole macroporous adsorbent resin, adsorption flow rate is 0.5BV/h, and resin column blade diameter length ratio is 1: 2, and sample solution concentration is 0.001g/mL, collects loading effluent, then water remove impurity 1BV；Utilizing volume fraction 5% ethanol solution eluting 1BV, elution flow rate is 0.5BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance I；Utilizing volume fraction 50% ethanol solution eluting 1BV, elution flow rate is 0.5BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance II, enriched substance I and enriched substance II is combined to obtain Hibiscus esculentus L. extract, is Hibiscus manihot L. compositions.
Embodiment 2 prepares Hibiscus manihot L. compositions
1) selecting flower of Hibiscus manihot L is crude drug；
2) utilize organic solvent reflux, extract, obtain crude extract, concretely comprise the following steps: by crude drug alcohol reflux 3 times, extract 2 hours every time, obtain crude extract；
3) by step 2) crude extract that obtains is enriched with, concretely comprises the following steps:
By step 2) crude extract that obtains adds water dispersing and dissolving, obtains the aqueous solution of crude extract, and making crude extract concentration in aqueous is 0.1g/mL；By the aqueous solution of crude extract by nonpolar macroporous adsorption resin, adsorption flow rate is 5BV/h, and resin column blade diameter length ratio is 1: 10, and sample solution concentration is 0.1g/mL, collects loading effluent, then water remove impurity 4BV；Utilizing volume fraction 25% ethanol solution eluting 5BV, elution flow rate is 5BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance I；Utilizing volume fraction 70% ethanol solution eluting 5BV, elution flow rate is 5BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance II, enriched substance I and enriched substance II is combined to obtain Hibiscus esculentus L. extract, is Hibiscus manihot L. compositions.
Embodiment 3 prepares Hibiscus manihot L. compositions
1) selecting flower of Hibiscus manihot L is crude drug；
2) utilize water or organic solvent reflux, extract, obtain crude extract, concretely comprise the following steps: by crude drug alcohol reflux 5 times, extract 3 hours every time, obtain crude extract；
3) by step 2) crude extract that obtains is enriched with, concretely comprises the following steps:
By step 2) crude extract that obtains adds water dispersing and dissolving, obtains the aqueous solution of crude extract, and making crude extract concentration in aqueous is 0.50g/mL；By the aqueous solution of crude extract by nonpolar macroporous adsorption resin, adsorption flow rate is 10BV/h, and resin column blade diameter length ratio is 1: 15, and sample solution concentration is 0.50g/mL, collects loading effluent, then water remove impurity 8BV；Utilizing volume fraction 50% ethanol solution eluting 10BV, elution flow rate is 10BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance I；Utilizing volume fraction 90% ethanol solution eluting 10BV, elution flow rate is 10BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance II, enriched substance I and enriched substance II is combined to obtain Hibiscus esculentus L. extract, is Hibiscus manihot L. compositions.
Embodiment 4 prepares Hibiscus manihot L. ethanol extract
With flower of Hibiscus manihot L as crude drug, with alcohol reflux 2-5 time, extract 0.5-3 hour every time, obtain Hibiscus manihot L. ethanol extract.
Embodiment 5 prepares Hibiscus manihot L. water extract
With flower of Hibiscus manihot L as crude drug, by water reflux, extract, 2-5 time, extract 0.5-3 hour every time, obtain Hibiscus manihot L. water extract.
Experiment effect example 1: dementia effect of the present invention
(1) experiment material
1. laboratory animal
ICR mice, male and female half and half, body weight 20-22g, Beijing Vital River Experimental Animals Technology Co., Ltd. provide.
2. medicine and reagent
By reagent: Hibiscus manihot L. compositions (being prepared by embodiment 1, be called for short compositions), Hibiscus manihot L. ethanol extract (being prepared by embodiment 4, be called for short ethanol extract), Hibiscus manihot L. water extract (being prepared by embodiment 5, be called for short water extract)；Scopolamine, is purchased from Nat'l Pharmaceutical & Biological Products Control Institute, product batch number: 100049-200308；Piracetam (traditional Chinese medicines quasi-word H44020779 is purchased from the big pharmacy of common people's sunlight, Beijing)；Normal saline (lot number: C13040602), Shangdong Hualu Pharmaceutical Co., Ltd.；Chloral hydrate (lot number: 20120720), Chemical Reagent Co., Ltd., Sinopharm Group.
3. equipment
Mice diving tower instrument, is divided into Room 5 in case, can measure 5 mices simultaneously.
(2) experimental technique and result
1. packet and administration
Mice is randomly divided into 12 groups by body weight, often group 10, i.e. it is respectively dosage group, Hibiscus manihot L. compositions high dose group in blank group, model group, positive drug group, Hibiscus manihot L. compositions low dose group, Hibiscus manihot L. compositions, dosage group, Hibiscus manihot L. ethanol extract high dose group in Hibiscus manihot L. ethanol extract low dose group, Hibiscus manihot L. ethanol extract, dosage group, Hibiscus manihot L. water extract high dose group in Hibiscus manihot L. water extract low dose group, Hibiscus manihot L. water extract；Blank group and model group are to normal saline；Positive drug group is to piracetam, and dosage is 0.72g/kg；In Hibiscus manihot L. compositions low dose group, Hibiscus manihot L. compositions, dosage group, Hibiscus manihot L. compositions high dose group dosage are respectively as follows: 0.18g/kg, 0.27g/kg, 0.45g/kg；In Hibiscus manihot L. ethanol extract low dose group, Hibiscus manihot L. ethanol extract, dosage group, Hibiscus manihot L. ethanol extract high dose group dosage are respectively 0.45g/kg, 0.68g/kg, 1.13g/kg；In Hibiscus manihot L. water extract low dose group, Hibiscus manihot L. water extract, dosage group, Hibiscus manihot L. water extract high dose group dosage are respectively 0.33g/kg, 0.50g/kg, 0.83g/kg.
2. experimental technique
Successive administration 7 days, is administered (accurate timing) lumbar injection scopolamine modeling in latter 30 minutes, is trained (Memory acquisition experiment) after 30 minutes, test (memory consolidation experiment) after 24 hours on the 7th day.Model group injection scopolamine modeling, is trained, tests after 24 hours for 30 minutes.Normal group is directly trained, and tests after 24 hours.
Diving tower Behaviors survey process
To put in diving tower instrument with 5 mices of group simultaneously, and adapt to environment 3 minutes, train 5 minutes, monitor record first time jumps onto the time (incubation period) of diving tower, the time in Safe period, and 5 minutes interior jumps off number of times (errors number).After 24 hours, carrying out memory consolidation test, be first put on diving tower by mice, record jumps off the time for the first time (getting an electric shock incubation period), the time in Safe period, and 5 minutes interior jumps off number of times (errors number).
Neurotransmitter detects
After Mei Zu behavioristics terminates, take mouse brain and be wrapped in masking foil and put into cryopreservation tube and keep sample, put method of exempting from and measure the activity of acetylcholinesterase in mouse brain.
3. statistical method
Using SAS8.0 statistical software to be analyzed, experimental result represents with mean ± standard error.Two sample t-test and non parametric tests (Mann-WhitneyTest) is used to compare two-by-two, use one factor analysis of variance (ANOVA) to compare between carrying out organizing more, group difference uses LSD (variance is neat) or Games-Howell method (heterogeneity of variance), memory consolidation test phase is respectively organized administration rat respectively compare with normal rats with model group rats, try to achieve group difference.
4. experimental result
Table 1 Hibiscus manihot L. various prepared product dementia effect experimental result
(note: data are means standard deviation；*Represent and compare P ＜ 0.01 with model group, have pole significant difference；*Represent and compare P ＜ 0.05 with model group, there is significant difference, ▲ represent and compare P ＞ 0.05 with model group, there is no significant difference, # represents and compares with blank group, P ＞ 0.05 is not significantly different from, and ## represents and compares with blank group, and there were significant differences for P ＜ 0.05).
(3) conclusion
As shown in Table 1, (1) model group mice ACHE value and normal group have pole significant difference (P ＜ 0.01), illustrate that lumbar injection scopolamine hydrobromide modeling causes the success of mice Model of Dementia.(2) positive drug group mice ACHE value compares with model group, P ＜ 0.01, has pole significant difference, and compares with blank group, and P ＞ 0.05 is not significantly different from, and illustrates that it has dementia drug action strong.(3) compositions dosage high, middle group mice ACHE value compares with model group, P ＜ 0.01, has pole significant difference, and compares with blank group, P ＞ 0.05 is not significantly different from, illustrating that its dementia drug action is strong, compositions low dose group mice ACHE value compares with model group, P ＜ 0.05, there is significant difference, and comparing with blank group, P ＞ 0.05 is not significantly different from, and illustrates that its dementia drug action is stronger.(4) ethanol extract high dose group mice ACHE value compares with model group, P ＜ 0.05, has significant difference, and compares with blank group, and P ＞ 0.05 does not has significant difference, illustrates that its dementia drug action is stronger.(5) water extract high dose group mice ACHE value compares with model group, P ＜ 0.05, has significant difference, and compares with blank group, and P ＞ 0.05 is not significantly different from, and illustrates that its dementia drug action is stronger.
To sum up, Hibiscus manihot L. compositions, ethanol extract high dose and water extract high dose have stronger dementia drug action, and Hibiscus manihot L. compositions dosage high, middle has strong dementia drug action, suitable with positive drug group, and the ability of learning and memory of model mice can be significantly improved, strengthen mice and passively escape the ability of electricity irritation, reduce errors number, reduce acetylcholine esterase active in Cerebral Cortex, thus reach the purpose improving memory with dementia.And it is relevant to present dosage.
The compositions of embodiment 2 and embodiment 3 preparation also is able to obtain experiment conclusion similar to Example 1 through verification experimental verification.
Experiment effect example 2 present invention has function of resisting myocardial ischemia
(1) experiment material
1. laboratory animal
SD rat, male and female half and half, body weight 190-220g.Thered is provided by Beijing Vital River Experimental Animals Technology Co., Ltd..
2. medicine and reagent
By reagent: Hibiscus manihot L. compositions (effective site mixture, prepared by embodiment 1, be called for short compositions), Hibiscus manihot L. ethanol extract (prepared by embodiment 4, be called for short ethanol extract), Hibiscus manihot L. water extract (being prepared by embodiment 5, be called for short water extract).Reagent: FUFANG DANSHEN DIWAN (lot number: 140207；Tasly Pharmaceutical Group Co., Ltd.)；Posterior pituitary injection (traditional Chinese medicines quasi-word H31022259, Shanghai No.1 Bio-Chemical Pharmacetical Industry Co., Ltd, 3U/mL)；Normal saline (lot number: C13040602), Shangdong Hualu Pharmaceutical Co., Ltd.；Chloral hydrate (lot number: 20120720), Chemical Reagent Co., Ltd., Sinopharm Group.
(2) experimental technique and result
1. packet and administration
After rat adaptability feeds one week, it is divided into 12 groups immediately, often group 10, male and female half and half, are i.e. respectively blank group, model group, positive drug group, compositions low dose group, middle dosage group, high dose group, ethanol extract low dose group, middle dosage group, high dose group, water extract low dose group, middle dosage group, high dose group.Blank group and model group are respectively as follows: 0.12g/kg, 0.18g/kg, 0.27g/kg to normal saline, positive drug group to FUFANG DANSHEN DIWAN, enriched substance compositions low dose group, middle dosage group, high dose group dosage；Ethanol extract low dose group, middle dosage group, high dose group dosage are respectively 0.30g/kg, 0.45g/kg, 0.68g/kg；Water extract low dose group, middle dosage group, high dose group dosage are respectively 0.22g/kg, 0.33g/kg, 0.50g/kg.
FUFANG DANSHEN DIWAN solution: dosage is 3 balls/kg, every sublingual vein causes Model of Acute Myocardial Ischemia to pituitrin by every kg body weight 4U sublingual vein injection of pituitrin (3U/mL).
2. myocardial infarction and ischemia model test
Blank group and model group gavage normal saline, administration group gavage respectively respectively organizes medicine, totally 7 days, after the 7th day is administered 1h, lumbar injection 10% chloral hydrate anesthesia, lie on the back and be fixed on operating-table, cause Model of Acute Myocardial Ischemia, after modeling 20min by every kg body weight 4U sublingual vein injection of pituitrin (3U/mL), abdominal aortic blood, being placed in the vacuum test tube of coagulant, 4 DEG C of-3500r/min are centrifuged 10min, separate serum and are centrifuged to obtain serum.Use creatine kinase (CK) and the content of lactic acid dehydrogenase (LDH) in biochemical process detection serum.
3. statistical method
Using SPSS17.0 system agent software to be analyzed, experimental result represents with mean ± standard error.Two sample t-test and non parametric tests (Mann-WhitneyTest) is used to compare two-by-two, using one factor analysis of variance (ANOVA) to compare between carrying out organizing, group difference uses LSD (variance is neat) or Games-Howell method (heterogeneity of variance) more.
4. experimental result
Table 2 Hibiscus manihot L. prepared product function of resisting myocardial ischemia experimental result
(note: data are means standard deviation；*Represent and compare P ＜ 0.01 with model group, have pole significant difference；*Represent and compare P ＜ 0.05 with model group, there is significant difference, ▲ represent and compare P ＞ 0.05 with model group, there is no significant difference, # represents and compares with blank group, P ＞ 0.05 is not significantly different from, and ## represents and compares with blank group, and there were significant differences for P ＜ 0.05).
(3) conclusion
As shown in Table 2: (1) model group rats CK value, LDH value and normal group have pole significant difference (P ＜ 0.01), illustrate that sublingual vein injection pituitrin causes Model of Acute Myocardial Ischemia success；(2) positive drug group CK and LDH two indexes compare with model group, P ＜ 0.01, have a pole significant difference, and compare with blank group, and P ＞ 0.05 does not has significant difference, illustrate positive drug to have by force to resist myocardial ischemia drug effect effect.(3) compositions high dose group CK and LDH two indexes compare with model group, P ＜ 0.01, have a pole significant difference, and compare with blank group, and P ＞ 0.05 does not has significant difference, illustrate it to have by force to resist myocardial ischemia drug effect effect；Middle dosage group CK, LDH compare with model group, P ＜ 0.05, have significant difference, and compare with blank group, P ＞ 0.05, are not significantly different from, illustrate that it has stronger dementia drug action.(4) ethanol extract high dose group rat CK, LDH compares with model group, and P ＜ 0.05 has significant difference；And compare with blank group, P ＞ 0.05, there is no significant difference；Illustrate it to have more by force to resist myocardial ischemia drug effect effect.(5) water extract high dose group rat CK and LDH compares with model group, and P ＜ 0.05 has significant difference；And compare with blank group, CKP ＞ 0.05, there is no significant difference, illustrate it to have more by force to resist myocardial ischemia drug effect effect.
To sum up, Hibiscus manihot L. compositions, ethanol extract and water extract high dose have the drug effect effect that resists myocardial ischemia more by force, and Hibiscus manihot L. compositions dosage high, middle is respectively provided with the drug effect effect that resists myocardial ischemia by force, and it is relevant to present dosage, wherein, the drug action of compositions high dose exceedes positive drug.
The compositions of embodiment 2 and embodiment 3 preparation also is able to obtain experiment conclusion similar to Example 1 through verification experimental verification.
Following embodiment all can realize the effect of above-mentioned experimental example.
The embodiment 1 of preparation: capsule
Prepare capsule with flower of Hibiscus manihot L for crude drug, specifically include following steps:
Taking flower of Hibiscus manihot L 1kg, 12 times of mass body fraction are 80% ethanol solution reflux, extract, 3 times, extract 1 hour every time, decompression and solvent recovery, obtains extract, and add water dispersing and dissolving, make concentration of aqueous solution for being equivalent to 0.1g/mL raw medicinal herbs, aqueous solution passes through low pole or nonpolar macroporous adsorption resin, and adsorption flow rate is 2BV/h, and resin column blade diameter length ratio is 1: 8, making medical material amount and resin volume ratio is 1: 6g/mL, collecting loading effluent, then water elution remove impurity 0.5BV, elution flow rate is 2BV/h；Volume fraction is 15% ethanol solution eluting 6BV, and elution flow rate is 2BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance I；Volume fraction is the ethanol solution eluting 5BV of 80%, and elution flow rate is 2BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance II, a combination thereof thing, adds customary adjuvant, and technique makes capsule routinely；
The content assaying method of total phenols:
Reference substance: rutin；
Reagent: 0.6% liquor ferri trichloridi, 0.9% potassium ferricyanide solution, 0.3% sodium dodecyl sulfate solution, methanol solution, 0.1mol/L hydrochloric acid solution；
Coloration method: accurate Hibiscus manihot L. prepared product composition sample solution of drawing is in right amount in 25mL brown volumetric flask, add methanol to 5mL, add 0.3% sodium dodecyl sulfate solution 2mL, and 0.6% ferric chloride-0.9% potassium ferricyanide mixed solution 1mL of 1: 1, dark place is placed 7min, is added to 25mL graduation mark with 0.1mol/L hydrochloric acid, shake up, 40min is placed in dark place, in case measuring, and retinue blank.Sample after above-mentioned colour developing is measured in 740 ± 2nm wave-length coverage, records its maximum absorbance value.Total phenol content is not less than 37% (mass percent) after measured.
The content assaying method of total alkaloids:
Reference substance: matrine；
Reagent: pH6.8 bromothymol blue solution: 0.07g bromothymol blue is dissolved in pH6.8 buffer solution (0.1mol/LNaH2PO4 and 0.1mol/LNaOH prepares) in 300mL.
Coloration method: it is appropriate that precision weighs Hibiscus manihot L. prepared product composition sample, is placed in 10mL brown volumetric flask, adds methanol ultrasonic dissolution and is diluted to scale, shake up, draw above-mentioned sample solution 1mL, be evaporated, add pH6.8 bromothymol blue solution 2mL, chloroform 7mL, close plug, acutely shake 2min, be transferred in separatory funnel, stand 2h, divide and take chloroform layer, retinue blank.Sample after above-mentioned colour developing is measured absorbance at 414nm, records its absorbance.Total alkaloid content is not less than 2% (mass percent) after measured.
Total steroid content assaying method:
Reference substance: cupreol；
Reagent: 5% vanillin-glacial acetic acid solution: precision weighs vanillin 0.5g and puts in 10mL volumetric flask, and acetate dissolution on the rocks is also settled to graduation mark, shakes up, to obtain final product.
Coloration method: accurate Hibiscus manihot L. prepared product composition sample solution of drawing, in right amount in cillin bottle, is put and volatilized solvent in boiling water bath, be cooled to room temperature.Retinue blank, each addition freshly prepared 5% vanillin-glacial acetic acid solution 0.2mL, perchloric acid 0.8mL, shake up, in 60 DEG C of waters bath with thermostatic control, be incubated 15 minutes, take out, cool down with cold water, add glacial acetic acid 5mL, shake up, at 546nm, measure absorbance.Total steroid content is not less than 5% after measured.
Index component content assay method:
Reference substance: chlorogenic acid, rutin, hyperin, isoquercitrin, Quercetin；
Chromatographic column: WatersSymmetryC18 chromatographic column (4.6 × 250mm, 5 μm)；Flow velocity: 1.0mL/min；Column temperature: 30 DEG C；Detection wavelength: 200-500nm；Flowing phase: acetonitrile (A)-0.05% phosphoric acid (B)；
Gradient condition
Chlorogenic acid content is not less than 0.05% after measured, and rutin content is not less than 0.2%, and Determination of Hyperoside is not less than 2%, and isoquercitrin content is not less than 1%, and quercetin content is not less than 0.1%；Described content refers to mass percent.
The embodiment 2 of preparation: tablet
Tablet is prepared for crude drug with flower of Hibiscus manihot L
Take above-mentioned raw materials medicine 1kg, 80% (volume fraction) ethanol solution reflux, extract, of 12 times of quality 3 times, extract 1 hour every time, decompression and solvent recovery, obtain extract, add water dispersing and dissolving, make concentration of aqueous solution for being equivalent to 0.1g/mL raw medicinal herbs, aqueous solution passes through low pole or nonpolar macroporous adsorption resin, and adsorption flow rate is 2BV/h, and resin column blade diameter length ratio is 1: 8, making medical material amount and resin volume ratio is 1: 6g/mL, collecting loading effluent, then water elution remove impurity 0.5BV, elution flow rate is 2BV/h；15% (volume fraction) ethanol solution eluting 6BV, elution flow rate is 2BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance I；80% (volume fraction) ethanol solution eluting 5BV, elution flow rate is 2BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance II, a combination thereof thing, adds customary adjuvant, and technique makes tablet routinely；
The content assaying method of total phenols:
Reference substance: rutin；
Reagent: 0.6% liquor ferri trichloridi, 0.9% potassium ferricyanide solution, 0.3% sodium dodecyl sulfate solution, methanol solution, 0.1mol/L hydrochloric acid solution；
Coloration method: accurate Hibiscus manihot L. prepared product composition sample solution of drawing is in right amount in 25mL brown volumetric flask, add methanol to 5mL, add 0.3% sodium dodecyl sulfate solution 2mL, and 0.6% ferric chloride-0.9% potassium ferricyanide mixed solution 1mL of 1: 1, dark place is placed 7min, is added to 25mL graduation mark with 0.1mol/L hydrochloric acid, shake up, 40min is placed in dark place, in case measuring, and retinue blank.Sample after above-mentioned colour developing is measured in 740 ± 2nm wave-length coverage, records its maximum absorbance value.Total phenol content is not less than 37% (mass fraction) after measured.
The content assaying method of total alkaloids:
Reference substance: matrine；
Reagent: pH6.8 bromothymol blue solution: 0.07g bromothymol blue is dissolved in pH6.8 buffer solution (0.1mol/LNaH2PO4Prepare with 0.1mol/LNaOH) in 300mL.
Coloration method: it is appropriate that precision weighs Hibiscus manihot L. prepared product composition sample, is placed in 10mL brown volumetric flask, adds methanol ultrasonic dissolution and is diluted to scale, shake up, draw above-mentioned sample solution 1mL, be evaporated, add pH6.8 bromothymol blue solution 2mL, chloroform 7mL, close plug, acutely shake 2min, be transferred in separatory funnel, stand 2h, divide and take chloroform layer, retinue blank.Sample after above-mentioned colour developing is measured absorbance at 414nm, records its absorbance.Total alkaloid content is not less than 2% (mass fraction) after measured.
Total steroid content assaying method:
Reference substance: cupreol；
Reagent: 5% vanillin-glacial acetic acid solution: precision weighs vanillin 0.5g and puts in 10mL volumetric flask, and acetate dissolution on the rocks is also settled to graduation mark, shakes up, to obtain final product.
Coloration method: accurate Hibiscus manihot L. prepared product composition sample solution of drawing, in right amount in cillin bottle, is put and volatilized solvent in boiling water bath, be cooled to room temperature.Retinue blank, each addition freshly prepared 5% vanillin-glacial acetic acid solution 0.2mL, perchloric acid 0.8mL, shake up, in 60 DEG C of waters bath with thermostatic control, be incubated 15 minutes, take out, cool down with cold water, add glacial acetic acid 5mL, shake up, at 546nm, measure absorbance.Total steroid content is not less than 5% after measured；Percent in above-mentioned content refers to mass fraction.
Index component content assay method:
Reference substance: chlorogenic acid, rutin, hyperin, isoquercitrin, Quercetin；
Chromatographic column: WatersSymmetryC18 chromatographic column (4.6 × 250mm, 5 μm)；Flow velocity: 1.0mL/min；Column temperature: 30 DEG C；Detection wavelength: 200-500nm；Flowing phase: acetonitrile (A)-0.05% phosphoric acid (B)；
Gradient condition
Chlorogenic acid content is not less than 0.05% after measured, and rutin content is not less than 0.2%, and Determination of Hyperoside is not less than 2%, and isoquercitrin content is not less than 1%, and quercetin content is not less than 0.1%；Percent in above-mentioned content refers to mass fraction.
The embodiment 3 of preparation: pill
Pill is prepared for crude drug with flower of Hibiscus manihot L
Take above-mentioned raw materials medicine 1kg, 12 times of quality 80% (volume fraction) ethanol solution reflux, extract, 3 times, extract 1 hour every time, decompression and solvent recovery, obtain extract, add water dispersing and dissolving, make concentration of aqueous solution for being equivalent to 0.1g/mL raw medicinal herbs, aqueous solution passes through low pole or nonpolar macroporous adsorption resin, and adsorption flow rate is 2BV/h, and resin column blade diameter length ratio is 1:8, making medical material amount and resin volume ratio is 1: 6g/mL, collecting loading effluent, then water elution remove impurity 0.5BV, elution flow rate is 2BV/h；15% (volume fraction) ethanol solution eluting 6BV, elution flow rate is 2BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance I；80% (volume fraction) ethanol solution eluting 5BV, elution flow rate is 2BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance II, a combination thereof thing, adds customary adjuvant, and technique makes pill routinely；
The content assaying method of total phenols:
Reference substance: rutin；
Reagent: 0.6% liquor ferri trichloridi, 0.9% potassium ferricyanide solution, 0.3% sodium dodecyl sulfate solution, methanol solution, 0.1mol/L hydrochloric acid solution；
Coloration method: accurate Hibiscus manihot L. prepared product composition sample solution of drawing is in right amount in 25mL brown volumetric flask, add methanol to 5mL, add 0.3% sodium dodecyl sulfate solution 2mL, and 0.6% ferric chloride-0.9% potassium ferricyanide mixed solution 1mL of 1: 1, dark place is placed 7min, is added to 25mL graduation mark with 0.1mol/L hydrochloric acid, shake up, 40min is placed in dark place, in case measuring, and retinue blank.Sample after above-mentioned colour developing is measured in 740 ± 2nm wave-length coverage, records its maximum absorbance value.Total phenol content is not less than 37% (mass fraction) after measured.
The content assaying method of total alkaloids:
Reference substance: matrine；
Reagent: pH6.8 bromothymol blue solution: 0.07g bromothymol blue is dissolved in pH6.8 buffer solution (0.1mol/LNaH2PO4Prepare with 0.1mol/LNaOH) in 300mL.
Coloration method: it is appropriate that precision weighs Hibiscus manihot L. prepared product composition sample, is placed in 10mL brown volumetric flask, adds methanol ultrasonic dissolution and is diluted to scale, shake up, draw above-mentioned sample solution 1mL, be evaporated, add pH6.8 bromothymol blue solution 2mL, chloroform 7mL, close plug, acutely shake 2min, be transferred in separatory funnel, stand 2h, divide and take chloroform layer, retinue blank.Sample after above-mentioned colour developing is measured absorbance at 414nm, records its absorbance.Total alkaloid content is not less than 2% (mass fraction) after measured.
Total steroid content assaying method:
Reference substance: cupreol；
Reagent: 5% vanillin-glacial acetic acid solution: precision weighs vanillin 0.5g and puts in 10mL volumetric flask, and acetate dissolution on the rocks is also settled to graduation mark, shakes up, to obtain final product.
Coloration method: accurate Hibiscus manihot L. prepared product composition sample solution of drawing, in right amount in cillin bottle, is put and volatilized solvent in boiling water bath, be cooled to room temperature.Retinue blank, each addition freshly prepared 5% vanillin-glacial acetic acid solution 0.2mL, perchloric acid 0.8mL, shake up, in 60 DEG C of waters bath with thermostatic control, be incubated 15 minutes, take out, cool down with cold water, add glacial acetic acid 5mL, shake up, at 546nm, measure absorbance.Total steroid content is not less than 5% after measured；Percent in above-mentioned content refers to mass fraction.
Index component content assay method:
Reference substance: chlorogenic acid, rutin, hyperin, isoquercitrin, Quercetin；
Chromatographic column: WatersSymmetryC18 chromatographic column (4.6 × 250mm, 5 μm)；Flow velocity: 1.0mL/min；Column temperature: 30 DEG C；Detection wavelength: 200-500nm；Flowing phase: acetonitrile (A)-0.05% phosphoric acid (B)；
Gradient condition is as follows:
Chlorogenic acid content is not less than 0.05% after measured, and rutin content is not less than 0.2%, and Determination of Hyperoside is not less than 2%, and isoquercitrin content is not less than 1%, and quercetin content is not less than 0.1%；Percent in above-mentioned content refers to mass fraction.
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all within the spirit and principles in the present invention, any modification, equivalent substitution and improvement etc. made, should be included within the scope of the present invention.
Claims (10)
1. a Hibiscus esculentus L. extract, it is characterized in that, including: phenolic compound, alkaloid compound and steroid, the content of phenolic compound is 10%-90%, the content of alkaloid compound is 1%-70%, and the content of steroid is 1%-60%.
2. the application in dementia of the Hibiscus esculentus L. extract described in claim 1.
3. the application in resisting myocardial ischemia of the Hibiscus esculentus L. extract described in claim 1.
4. the preparation containing Hibiscus esculentus L. extract, it is characterised in that include the Hibiscus esculentus L. extract described in right 1 and adjuvant.
A kind of preparation containing Hibiscus esculentus L. extract, it is characterised in that described adjuvant is one or more in preservative, antioxidant, coloring agent, thickening agent and stabilizer, bulking agent, sweeting agent, acidity agent, brightening agent or spice；The dosage form of described preparation is pharmaceutics acceptable any conventional dosage form or long-acting and slow releasing preparation, controlled release preparation, targeting preparation；The dosage form of said preparation includes tablet, capsule, granule, oral liquid, syrup, drop pill, injection, freeze dried powder, slow releasing tablet or micropill.
6. the preparation method of a Hibiscus esculentus L. extract, it is characterised in that comprise the following steps:
1) using Hibiscus manihot L. or the former plant of Hibiscus manihot L. congener as crude drug；
2) utilize water or organic solvent reflux, extract, obtain crude extract；
3) by step 2) crude extract that obtains is enriched with.
The preparation method of a kind of Hibiscus esculentus L. extract, it is characterised in that described crude drug is flower of Hibiscus manihot L.
The preparation method of a kind of Hibiscus esculentus L. extract, it is characterised in that the method for described enrichment is chromatography or solvent extraction.
9. according to the preparation method of a kind of Hibiscus esculentus L. extract described in any one of claim 6 to 8, it is characterised in that step 2) concretely comprise the following steps: by starting material with water or alcohol reflux 2-5 time, extract 0.5-3 hour every time, obtain crude extract.
10. according to the preparation method of a kind of Hibiscus esculentus L. extract described in any one of claim 6 to 8, it is characterized in that, step 3) concretely comprise the following steps: by step 2) crude extract that obtains adds water dispersing and dissolving, obtaining the aqueous solution of crude extract, making crude extract concentration in aqueous is 0.001-0.50g/mL；By the aqueous solution of crude extract by low pole or nonpolar macroporous adsorption resin, adsorption flow rate is 0.5-10BV/h, and resin column blade diameter length ratio is 1: (2-15), and sample solution concentration is 0.001-0.50g/mL, collects loading effluent, then water remove impurity 0-8BV；Utilizing volume fraction 5%-50% ethanol solution eluting 1-10BV, elution flow rate is 0.5-10BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance I；Utilizing volume fraction 50%-90% ethanol solution eluting 1-10BV, elution flow rate is 0.5-10BV/h, collects eluent, recycling design, drying under reduced pressure, obtains enriched substance II, and enriched substance I and enriched substance II are combined to obtain Hibiscus esculentus L. extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610007286.5A CN105816488A (en) | 2016-01-06 | 2016-01-06 | Drug capable of resisting dementia and myocardial ischemia, and biologically-active substances, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610007286.5A CN105816488A (en) | 2016-01-06 | 2016-01-06 | Drug capable of resisting dementia and myocardial ischemia, and biologically-active substances, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105816488A true CN105816488A (en) | 2016-08-03 |
Family
ID=56986951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610007286.5A Pending CN105816488A (en) | 2016-01-06 | 2016-01-06 | Drug capable of resisting dementia and myocardial ischemia, and biologically-active substances, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105816488A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123849A (en) * | 2019-05-18 | 2019-08-16 | 山东云舒生命科学有限公司 | A kind of element of turning green of anti-aging |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084939A (en) * | 2007-06-13 | 2007-12-12 | 淄博济世保健食品科技有限公司 | Abelmoschus manihot health care hard capsule |
| CN101084941A (en) * | 2007-06-13 | 2007-12-12 | 淄博济世保健食品科技有限公司 | Abelmoschus manihot health care soft opaque capsule |
| CN101129421A (en) * | 2007-08-13 | 2008-02-27 | 淄博济世保健食品科技有限公司 | Golden flower mallow health care pill |
| CN105055465A (en) * | 2015-07-16 | 2015-11-18 | 河南科技大学 | Abelmoschus manihot extract used for sedation and hypnosis and extraction method thereof |
| CN105055466A (en) * | 2015-07-16 | 2015-11-18 | 河南科技大学 | Drug material with hypnotic effect and preparation method thereof |
-
2016
- 2016-01-06 CN CN201610007286.5A patent/CN105816488A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084939A (en) * | 2007-06-13 | 2007-12-12 | 淄博济世保健食品科技有限公司 | Abelmoschus manihot health care hard capsule |
| CN101084941A (en) * | 2007-06-13 | 2007-12-12 | 淄博济世保健食品科技有限公司 | Abelmoschus manihot health care soft opaque capsule |
| CN101129421A (en) * | 2007-08-13 | 2008-02-27 | 淄博济世保健食品科技有限公司 | Golden flower mallow health care pill |
| CN105055465A (en) * | 2015-07-16 | 2015-11-18 | 河南科技大学 | Abelmoschus manihot extract used for sedation and hypnosis and extraction method thereof |
| CN105055466A (en) * | 2015-07-16 | 2015-11-18 | 河南科技大学 | Drug material with hypnotic effect and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 梅洪睿: "金花葵中提取生物活性物质的研究", 《中国优秀硕士学位论文全文数据库工程科技Ⅰ辑》 * |
| 窦德强: "《中药化学》", 30 April 2012, 湖南科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123849A (en) * | 2019-05-18 | 2019-08-16 | 山东云舒生命科学有限公司 | A kind of element of turning green of anti-aging |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103977179B (en) | Medicine substance with anti-dementia effect and preparation method and application thereof | |
| CN103054907A (en) | Propolis flavonoid extractive and preparation method thereof | |
| CN102743401B (en) | Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia | |
| CN102641317A (en) | Golden wave extract and application thereof in preparation of antidiabetic agent | |
| CN102058814B (en) | General flavone extractive of four medicaments including grassleaf sweetflag rhizome and preparation method thereof | |
| CN104435034A (en) | PNS (panax notoginseng saponins) and preparation method thereof | |
| CN101313922A (en) | Method for obtaining extract from several frequently seen plants and uses of the extract | |
| CN106138298A (en) | A kind of composition with reducing blood lipid hypoglycemic activity and preparation method and application | |
| CN106491680B (en) | A Chinese medicinal composition for preventing or treating senile dementia, and its preparation method | |
| CN1989984B (en) | Chuanxiong rhizome effective ingredient, preparing method, preparation and use thereof | |
| CN101601700A (en) | Valeriana amurensis effective part extract and method of quality control thereof and medical usage | |
| CN103977180B (en) | Traditional Chinese medicine substance formula with anti-depression effect and preparation method and application thereof | |
| CN105816488A (en) | Drug capable of resisting dementia and myocardial ischemia, and biologically-active substances, preparation method and application thereof | |
| CN101766664B (en) | Detection method of total saponin of Radix Ilicis Asprellae | |
| CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN100478015C (en) | Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method | |
| CN106420850B (en) | Compositions extracted from gingko biloba leaves and its preparing the application in Shu Xuening injection | |
| CN104257756B (en) | The application in preparing hypoglycemic medicine of a kind of Cortex Mori fatty oil | |
| CN105560607A (en) | Preparation method and application of preparation having antithrombotic and anti-myocardial ischemic effects | |
| CN103110890B (en) | Effective part of Xierigasiwei (Mongolian medicine) as well as preparation method, quality detection method and application thereof | |
| CN106420851B (en) | A kind of Shu Xuening injection and preparation method thereof | |
| CN102100721A (en) | Method for producing total flavonoids of chrysanthemum | |
| CN110694025A (en) | Eight-treasure intelligence-benefiting compound and preparation method and application thereof | |
| CN103800389A (en) | Hypoglycemic active ingredient in Sarcodon leucopus and preparation method and application thereof | |
| CN112920146B (en) | Sesquiterpenoids, preparation method thereof and application thereof in preparing anti-inflammatory drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |
|
| RJ01 | Rejection of invention patent application after publication |